The role of platelet-activating factor in human fetal lung maturation

Hoffman, Dennis R.; Truong, Chi-Thanh; Johnston, John M.

doi:10.1016/0002-9378(86)90081-5

Cited by 42 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It may be that it is a manifestation of the normal surfactant maturation process, which normally commences, on average, at 34 weeks [1], and which has been unaffected by the membrane rupture. Studies on plate let-activating factor (PAF) in amniotic fluid have suggested that the two processes might be commonly related [10]. PAF in amniotic fluid largely comes from fetal lung and it has been postulated that increased PAF produc tion may be a common initial pathway for increased synthesis of glycerophospholipids in the lung required for surfactant produc tion on the one hand and for stimulation of prostaglandin E2 secretion into the amniotic fluid from the amnion on the other.…”

Section: Discussionmentioning

confidence: 99%

Surfactant Maturation and Preterm Premature Membrane Rupture: A Case Study

James¹,

Eddowes²,

Rodgers³

et al. 1990

Fetal Diagn Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Surfactant Maturation and Preterm Premature Membrane Rupture: A Case Study

James¹,

Eddowes²,

Rodgers³

et al. 1990

Fetal Diagn Ther

View full text Add to dashboard Cite

show abstract

“…HofTman et al [3] proposed that PAF plays a role in fetal pulmonary maturation by accel erating glycogenolysis which may supply ener gy, glycerol and acetyl Co-A needed for sur factant synthesis. We were unable to show a correlation between BTG and PF4 with pul monary maturity parameters.…”

Section: Discussionmentioning

confidence: 99%

“…If we extrapolate the time-dependent in crease in PAF production by cultured human lung tissue to the intact fetus [3], one expects that fetal pulmonary PAF increases as the pregnancy approaches term. This could lead to increased fetal platelet release of BTG and PF4 with a subsequent increase in amniotic fluid levels.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Amniotic Fluid Platelet Factor 4 and Beta- Thromboglobulin

et al. 1993

View full text Add to dashboard Cite

Platelet activating factor (PAF), a powerful platelet activator, has been identified in huma embryos and fetuses, and may induce fetal lung maturation. The potential effect of PAF on fetal platelets as indicated by release of β-thromboglobulin (BTG) and platelet factor 4 (PF4) has not been investigated. We measured BTG and PF4 in amniotic fluid from 78 genetic and 35 pulmonary maturity amniocenteses. BTG and PF4 were higher in the genetic amniocentesis samples (p < 0.001 in each case) than in the lung maturity samples. BTG and PF4 did not correlate with the pulmonary maturity parameters as measured by the lecithin to sphingomyelin ratio and phosphatidylglycerol concentration. Our findings suggest a fetal origin of BTG and PF4 in amniotic fluid.

show abstract

“…We also wondered whether PAF uptake was an ubiquitous phenomenon or whether there were privileged lung cell types involved in the processing of this bioactive material. The latter question is of importance in view of recent reports suggesting a role of PAF in human lung maturation (19) as well as the potential contribution of this molecule to airway inflammatory processes. In this study, the metabolic profile of PAF metabolism and cellular involvement was determined in the isolated perfused rat lung.…”

Section: Introductionmentioning

confidence: 99%

Metabolism of platelet-activating factor in isolated perfused rat lung.

Haroldsen¹,

Voelkel²,

Henson³

et al. 1987

J. Clin. Invest.

View full text Add to dashboard Cite

The administration of platelet-activating factor (PAF) into the airway system of the lung is known to cause profound effects, yet little is known about the metabolism of this active lipid mediator. 3H-Labeled PAF administered into the airway of isolated rat lungs was rapidly and extensively metabolized. The tissue retained 96% of the administered radiolabel while the perfusate contained 4%. Characterization of the tissue retained lipid indicated metabolism into lyso-PAF (3.3%), phosphatidylcholine (82.3%), neutral lipid (1.7%) and intact PAF (10.2%). Analysis of tissue phosphatidylcholine by mass spectrometric techniques revealed metabolism of PAF to 1-0-hexadecyl-2-arachidonoyl-GPC, which represented 20-23% of the administered radiolabeled hexadecyl-PAF. These findings support the hypothesis that a relationship between PAF and arachidonate metabolism exists at the intact organ level. Autoradiographic analysis of the cellular distribution of the radiolabeled PAF metabolites in the lung tissue indicated labeling of two cell types, the alveolar type II cell and the nonciliated bronchiolar epithelial cell (Clara cell).

show abstract

The role of platelet-activating factor in human fetal lung maturation

Cited by 42 publications

References 17 publications

Surfactant Maturation and Preterm Premature Membrane Rupture: A Case Study

Surfactant Maturation and Preterm Premature Membrane Rupture: A Case Study

Amniotic Fluid Platelet Factor 4 and Beta- Thromboglobulin

Metabolism of platelet-activating factor in isolated perfused rat lung.

Contact Info

Product

Resources

About